

Proprietary Information of United Healthcare: The information contained in this document is proprietary and the sole property of United HealthCare Services, Inc. Unauthorized copying, use and distribution of this information are strictly prohibited. Copyright 2020 United HealthCare Services, Inc.



UnitedHealthcare® Community Plan Medical Benefit Drug Policy

Review at Launch for New to Market Medications

Policy Number: CS2020D0060D
Effective Date: **TBD**

Formatted: Font: Bold

Table of Contents	Page
Coverage Rationale	1
Applicable Codes	2
Background	2
References	2
Policy History/Revision Information	3
Instructions for Use	Error! Bookmark not defined.

Related Community Plan Policy

- [Off-Label/Unproven Specialty Drug Treatment](#)

Commercial Policy

- [Review at Launch for New to Market Medications](#)

Related Document

- [Review at Launch Medication List](#)

Application

This Medical Benefit Drug Policy only applies to the state of Louisiana.

Coverage Rationale

This drug policy applies to new medications that are:

- Food and Drug Administration (FDA) approved;
- Healthcare provider administered; **and**
- Reimbursable on a member's medical benefit

This policy does not apply to:

- Medications used for the treatment of oncological conditions (these therapies are addressed by other policies/programs)
- Investigational/experimental medications
- Antibiotics/anti-infectives
- Nuclear pharmacy products (materials used in nuclear medicine procedures)
- Vaccines

All new medications that are identified as being subject to this policy will be placed on the [Review at Launch Medication List](#) and reviewed upon FDA approval.

Medications will be reviewed based on:

- Health plan benefits and whether the medication is a covered/reimbursable service; **and**
- Medical necessity

Medical necessity reviews will be conducted using the following:

- A UnitedHealthcare Pharmacy and Therapeutics (UHC P&T) approved medical **benefit** drug policy; **or**

Formatted: Font: Bold

Formatted: Font: Bold

Review at Launch for New to Market Medications
UnitedHealthcare Community Plan Medical Benefit Drug Policy

Page 1 of 3
Effective **TBD**

Proprietary Information of UnitedHealthcare. Copyright 2020 United HealthCare Services, Inc.

- All of the following:
 - o FDA approved labeling, including but not limited to indication, patient age requirements, dosing recommendations, contraindications, and clinical trial inclusion criteria (ex. genetic testing, comorbid conditions); **and**
 - o Compendia (if available); **and**
 - o Current standard of care, as per evidenced based literature (if available)

The medications identified on the [Review at Launch Medication List](#) will be subject to this policy until such time that UnitedHealthcare determines pre-service reviews are no longer necessary or the drugs are added to the Prior Authorization List.

Claims submitted for a medication identified on the [Review at Launch Medication List](#) will be reviewed against health plan benefits and for medical necessity, as per the above.

In accordance with the Federal Early and Periodic Screening, Diagnostic and Treatment (EPSDT) requirements, children less than 21 years of age are entitled to receive all Medicaid coverable and medically necessary services.

Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by federal, state, or contractual requirements and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

HCPSC Code	Description
C9399	Unclassified drugs or biologicals
J3490	Unclassified drugs
J3590	Unclassified biologics

Background

The Review at Launch program provides UnitedHealthcare the ability to review, evaluate, and implement programs for new to market medications. Additionally, it provides the opportunity to assess the coverage status of these new medications, and properly re-direct providers to State Medicaid Fee-For-Service programs when appropriate. The medications may be added to the Prior Authorization List once they have been evaluated by the UnitedHealthcare Pharmacy and Therapeutics Committee and a final utilization management strategy has been determined.

References

1. AHFS Drug information [website]. Available at: <http://www.ahfsdruginformation.com/>. Accessed ~~September 8, 2020~~~~July 30, 2019~~.
2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2017. Available at: <http://www.goldstandard.com>. Accessed ~~September 8, 2020~~~~July 30, 2019~~.
3. Micromedex 2.0 [database online]. Truven Health Analytics, Inc. Greenwood Village, CO. Available at: <http://www.micromedexsolutions.com>. Accessed ~~September 8, 2020~~~~July 30, 2019~~.
4. UpToDate [database online]. Available at: <http://www.uptodate.com/>. Accessed ~~September 8, 2020~~~~July 30, 2019~~.
- 4-5. MCG™ Care Guidelines, Ambulatory Care 24th edition. Available at: <http://careweb.careguidelines.com/>.

5. MCG[®] Care Guidelines, Ambulatory Care, [23rd Edition]. Available at: <http://careweb.careguidelines.com/>. Accessed July 30, 2019.

Policy History/Revision Information

Date	Summary of Changes
TBD	Annual review. Updated references. Minor update to coverage rationale with no changes to clinical intent.

Formatted: Font: Bold

Formatted: Font: Bold